TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19667268

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with paclitaxel (AC followed by paclitaxel)
Number of subjects: 1942

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy without paclitaxel (AC only)
Number of subjects: 1942

Group type: EXPERIMENTAL
Intervention: High Tau protein expression
Number of subjects: 1942

Group type: EXPERIMENTAL
Intervention: Tau expression
Number of subjects: 1942
Study: 17328809

Group type: EXPERIMENTAL
Intervention: Back School Programme (n = 50)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Clinic group (n = 52)
Number of subjects: 102
Study: 15025551

Group type: EXPERIMENTAL
Intervention: Inhaled iloprost 2.5 or 5 microg six or nine times daily for 12 weeks
Number of subjects: 101
Study: 11683189

Group type: EXPERIMENTAL
Intervention: CVC (percutaneous longlines)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Peripheral cannulae
Number of subjects: 49
Study: 10806696

Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg orally
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intravenous magnesium sulfate (control)
Number of subjects: 14
Study: 1996187

Group type: COMPARATOR
Intervention: Slow release diltiazem (maximum dose 360 mg daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Slow release diltiazem (minimum dose 120 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Slow release diltiazem (up to 360 mg daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Slow release diltiazem
Number of subjects: 24
Study: 6434435

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testosterone cyclohexanecarboxylate
Number of subjects: 0
Study: 30371982

Group type: EXPERIMENTAL
Intervention: One-to-one low-intensity interventions (LIIs)
Number of subjects: 8
Study: 29524476

Group type: EXPERIMENTAL
Intervention: MVP ON phase
Number of subjects: 70

Group type: COMPARATOR
Intervention: MVP OFF phase
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: MVP ON and OFF phases
Number of subjects: 70
Study: 26768753

Group type: EXPERIMENTAL
Intervention: Guided audio-visual relaxation intervention
Number of subjects: 28

Group type: COMPARATOR
Intervention: Recorded sickle cell discussion (Control)
Number of subjects: 28
Study: 23307827

Group type: EXPERIMENTAL
Intervention: Oral treprostinil (0.25 mg tablets)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 349
Study: 21321676

Group type: EXPERIMENTAL
Intervention: Trimmed nasal cannula (TNC)
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: Nasal mask (NM)
Number of subjects: 836

Group type: COMPARATOR
Intervention: Nasal cannula (NC)
Number of subjects: 836
Study: 19525834

Group type: EXPERIMENTAL
Intervention: Steroid caudal epidural injections (CEI) containing 12 mL of xylocaine 2% and 1 mL of betamethasone dipropionate and betamethasone phosphate (2 + 5) mg/dL
Number of subjects: 183

Group type: COMPARATOR
Intervention: Water for Injection (WFI) caudal epidural injections containing 12 mL of xylocaine 2% and 8 mL of WFI
Number of subjects: 183
Study: 18181310

Group type: EXPERIMENTAL
Intervention: Hypertonic sodium chloride enema
Number of subjects: 300

Group type: COMPARATOR
Intervention: Hypertonic sodium phosphate enema
Number of subjects: 300
Study: 15149416

Group type: EXPERIMENTAL
Intervention: Cardioversion
Number of subjects: 38
Study: 11395819

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 11
Study: 10382124

Group type: EXPERIMENTAL
Intervention: Dual therapy (omeprazole, 20 mg bid, and amoxicillin, 1 gm bid, or clarithromycin, 500 mg tid)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Triple therapy (omeprazole, 20 mg bid, plus metronidazole, 500 mg bid, and amoxicillin, 1,000 mg bid, or clarithromycin, 500 mg tid)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Triple therapy (omeprazole, 20 mg bid, plus metronidazole, 500 mg bid, plus tetracycline, 500 mg qid, or doxycycline, 100 mg tid)
Number of subjects: 369
Study: 10155202

Group type: EXPERIMENTAL
Intervention: Palmaz-Schatz stent
Number of subjects: 50

Group type: COMPARATOR
Intervention: Strecker stent
Number of subjects: 50
Study: 2789925

Group type: EXPERIMENTAL
Intervention: 10 mg ICS 205-930
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20 mg ICS 205-930
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ICS 205-930
Number of subjects: 12
Study: 795183

Group type: EXPERIMENTAL
Intervention: Diflucortolone valerate fatty ointment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fluocinolone acetonide ointment
Number of subjects: 60
Study: 30537098

Group type: EXPERIMENTAL
Intervention: Progesterone (400 mg/day for 7 days)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 46

Group type: COMPARATOR
Intervention: Progesterone and Placebo
Number of subjects: 46
Study: 26419583

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain Shirota-fermented milk (LcS-FM)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control milk (CM)
Number of subjects: 96
Study: 26349284

Group type: EXPERIMENTAL
Intervention: RFA-1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RFA-2
Number of subjects: 40
Study: 23213077

Group type: EXPERIMENTAL
Intervention: Repetitive facilitative exercise (RFE) - 100 standardized movements of at least 5 joints of the affected upper extremity, 40 min/day, 5 days/week for 4 weeks.
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional upper-extremity rehabilitation program; same duration and frequency as RFE.
Number of subjects: 52
Study: 22433807

Group type: EXPERIMENTAL
Intervention: Combination of reamberin and cycloferon
Number of subjects: 160

Group type: COMPARATOR
Intervention: Generally accepted therapy
Number of subjects: 160
Study: 19447808

Group type: EXPERIMENTAL
Intervention: High RVP (RVP 94%, n = 24)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Low RVP (RVP 0%, n = 189)
Number of subjects: 213
Study: 16855141

Group type: EXPERIMENTAL
Intervention: Prolactin response to hypoglycemia in SSc patients
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Prolactin response to hypoglycemia in PsA patients
Number of subjects: 2

Group type: COMPARATOR
Intervention: Growth hormone response to hypoglycemia in SSc and PsA patients
Number of subjects: 2

Group type: COMPARATOR
Intervention: Growth hormone response to hypoglycemia in healthy controls
Number of subjects: 2
Study: 15087264

Group type: EXPERIMENTAL
Intervention: High procyanidin chocolate (200 mg of flavanols and related procyanidins)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low procyanidin chocolate (less than 10 mg of polyphenols)
Number of subjects: 18
Study: 10958263

Group type: EXPERIMENTAL
Intervention: New serotonergic-noradrenergic antidepressant
Number of subjects: 216
Study: 9295890

Group type: EXPERIMENTAL
Intervention: Thrombolytic substances during acute myocardial infarction
Number of subjects: 175
Study: 7956958

Group type: EXPERIMENTAL
Intervention: Planned chronic injection sclerotherapy (at three weekly intervals)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Demand injection sclerotherapy (after variceal bleeds only)
Number of subjects: 40
Study: 3234187

Group type: EXPERIMENTAL
Intervention: Timolol 0.5% and placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Indomethacin 1% and placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Timolol 0.5% and Indomethacin 1%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo and placebo
Number of subjects: 40
Study: 28956620

Group type: EXPERIMENTAL
Intervention: Combination treatment (CBT + sertraline)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 488

Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 488
Study: 28582570

Group type: EXPERIMENTAL
Intervention: Filorexant 10 mg
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 25589680

Group type: EXPERIMENTAL
Intervention: 4-week pre quit bupropion
Number of subjects: 95

Group type: COMPARATOR
Intervention: 1-week pre quit bupropion (standard run-in)
Number of subjects: 95
Study: 24660606

Group type: EXPERIMENTAL
Intervention: Pricking-bloodletting cupping at Dazhui (GV 14) under acupuncture anesthesia at Hegu (LI 4) and Quchi (LI 11)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Pricking-bloodletting cupping at Dazhui (GV 14)
Number of subjects: 38
Study: 21533995

Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa 100 mg three times on day 1
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa 100 mg with COMT-inhibitor entacapone (EN) on day 2
Number of subjects: 16

Group type: COMPARATOR
Intervention: Comparison between day 1 and day 2
Number of subjects: 16
Study: 19706352

Group type: EXPERIMENTAL
Intervention: Uninterrupted group
Number of subjects: 312
Study: 16573871

Group type: EXPERIMENTAL
Intervention: BBC prison study
Number of subjects: 0
Study: 14627174

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (Symbicort Turbuhaler) 160/4.5 mg, two inhalations b.i.d.
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (Symbicort Turbuhaler)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Budesonide plus formoterol separate inhalers
Number of subjects: 320
Study: 10807021

Group type: EXPERIMENTAL
Intervention: Case Management (CM)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 302
Study: 9356109

Group type: EXPERIMENTAL
Intervention: 50% N2O in oxygen for 10 min
Number of subjects: 20

Group type: COMPARATOR
Intervention: 50% nitrogen (control group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: N2O group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 8382424

Group type: EXPERIMENTAL
Intervention: Intravaginal application of yoghurt
Number of subjects: 32
Study: 2859077

Group type: EXPERIMENTAL
Intervention: Dexamphetamine sulphate tablets 10 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dexamphetamine sulphate tablets 30 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dexedrine Spansules 10 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mazindol 4 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fencamfamin hydrochloride 60 mg
Number of subjects: 20
Study: 29540571

Group type: EXPERIMENTAL
Intervention: Compliance-linked incentives (Rs30 or $0.50 of phone talk time)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Mobile phone reminders
Number of subjects: 608

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 608
Study: 27550361

Group type: EXPERIMENTAL
Intervention: AZD5847 at 500 mg twice daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: AZD5847 at 500 mg once daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: AZD5847 at 1,200 mg once daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: AZD5847 at 800 mg twice daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Combination of isoniazid, rifampin, ethambutol, and pyrazinamide (standard chemotherapy)
Number of subjects: 15
Study: 24907877

Group type: EXPERIMENTAL
Intervention: 30 ml 0.5% bupivacaine (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 30 ml 0.5% levobupivacaine (Group L)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison of both groups (Group B and Group L)
Number of subjects: 60
Study: 23337198

Group type: EXPERIMENTAL
Intervention: Exercise (90% ventilatory threshold)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 20
Study: 21962098

Group type: EXPERIMENTAL
Intervention: Nasal carbon dioxide (10 mL/s for 10 seconds per nostril)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study: 18405155

Group type: EXPERIMENTAL
Intervention: Moxibustion at 'heat sensitive points', treated once a day for 10 days.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cetirizine Hydrochloride, 10 mg orally, once daily for 10 days.
Number of subjects: 120
Study: 16878213

Group type: EXPERIMENTAL
Intervention: Herbal dentifrice
Number of subjects: 48

Group type: COMPARATOR
Intervention: Dentifrice with triclosan and fluoride (positive control)
Number of subjects: 48
Study: 12514658

Group type: EXPERIMENTAL
Intervention: Zofenopril (30-60 mg/day)
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Lisinopril (5-10 mg/day)
Number of subjects: 1024
Study: 10462245

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted influenza vaccine (FLUAD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-adjuvanted subunit vaccine
Number of subjects: 0
Study: 8698756

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (150 mg/day) for seven days before operation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2016621

Group type: COMPARATOR
Intervention: Chemotherapy (CT) alone (CYC/ADR)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Chemotherapy with concurrent radiation therapy (CT/RT)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both CT and CT/RT groups
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: CT/RT arm
Number of subjects: 62
Study: 6992677

Group type: EXPERIMENTAL
Intervention: Trimethoprim (100 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin macrocrystals (100 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (40 mg/200 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31868819

Group type: EXPERIMENTAL
Intervention: Combined drug and wedge-shaped pillow (WSP) treatment for 3 months after 2 weeks of drug only and drug plus WSP sequences.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Drug only sequence for 2 weeks.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combined drug and WSP treatment after 3 months.
Number of subjects: 14
Study: 30661716

Group type: EXPERIMENTAL
Intervention: Minced skin grafting applied over the study area
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control area (no minced skin grafting)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Minced skin grafting
Number of subjects: 30
Study: 28671507

Group type: EXPERIMENTAL
Intervention: Clarithromycin (CLM) 500 mg every 12 hours for 3 days with one-stage full-mouth ultrasonic debridement (FMUD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo with one-stage full-mouth ultrasonic debridement (FMUD)
Number of subjects: 40
Study: 25911394

Group type: COMPARATOR
Intervention: Aperture fixation using femoral and tibial joint-line fixation with a femoral cannulated interference screw and a tibial cannulated interference retrograde screw
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Suspensory fixation using femoral and tibial cortical buttons
Number of subjects: 64

Group type: COMPARATOR
Intervention: Aperture fixation
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Suspensory fixation
Number of subjects: 64
Study: 24235064

Group type: COMPARATOR
Intervention: 4-week supervised exercise program
Number of subjects: 22

Group type: COMPARATOR
Intervention: 8-week supervised exercise program
Number of subjects: 22
Study: 21349913

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrostimulation (NMES) for 6 weeks, delivered to quadriceps and hamstring muscles (35 Hz)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrostimulation (NMES)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 15
Study: 19918852

Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 472

Group type: COMPARATOR
Intervention: Open resection
Number of subjects: 472
Study: 17628232

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab or Certolizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-integrin α4 therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunostimulating therapy (granulocyte-monocyte colony-stimulating factor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New therapies
Number of subjects: 0
Study: 15149889

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Valsartan 80 mg/day (Control)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normotensive subjects (Control)
Number of subjects: 24
Study: 11298390

Group type: EXPERIMENTAL
Intervention: Pulsed radio frequency electromagnetic fields (900 MHz, pulsed at 217 Hz, average power flux density 1 W/m2)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 8
Study: 9204086

Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel
Number of subjects: 42

Group type: COMPARATOR
Intervention: Tretinoin 0.025% gel
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Adapalene aqueous 0.03% and 0.1% gels
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Adapalene alcoholic 0.03% and 0.1% gels
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Adapalene gel vehicles or patch alone
Number of subjects: 42

Group type: COMPARATOR
Intervention: TEWL measurement at tretinoin site
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: TEWL measurement at adapalene sites
Number of subjects: 42
Study: 7962382

Group type: EXPERIMENTAL
Intervention: In-vitro fertilization (IVF)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Ovarian stimulation without IVF
Number of subjects: 99

Group type: COMPARATOR
Intervention: Natural conception
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Oocyte donation
Number of subjects: 99
Study: 3630816

Group type: EXPERIMENTAL
Intervention: MLCu250 + 0.3 mg estradiol releasing about 1 microgram per day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: MLCu250 + 1.0 mg estradiol releasing about 3 micrograms per day
Number of subjects: 90

Group type: COMPARATOR
Intervention: MLCu250
Number of subjects: 90
Study: 29147969

Group type: EXPERIMENTAL
Intervention: Dietary phospholipids (PLs) at 8.5 g kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary phospholipids (PLs) at increasing levels (8.5 to 41.5 g kg‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary phospholipids (PLs) at increasing levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary phospholipids (PLs)
Number of subjects: 0
Study: 27648684

Group type: COMPARATOR
Intervention: 20 μg Engerix-B® with 0, 1, 6 month intervals
Number of subjects: 1169

Group type: COMPARATOR
Intervention: 20 μg Kangtai hepatitis B vaccine with 0, 1, 6 month intervals
Number of subjects: 1169

Group type: EXPERIMENTAL
Intervention: 60 μg Kangtai hepatitis B vaccine with 0, 2 month intervals
Number of subjects: 1169

Group type: COMPARATOR
Intervention: 20 μg Huabei hepatitis B vaccine with 0, 1, 6 month intervals
Number of subjects: 1169
Study: 24742322

Group type: EXPERIMENTAL
Intervention: Brief manual-guided motivational intervention with a phone booster at 10 days
Number of subjects: 600

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Brief manual-guided motivational intervention
Number of subjects: 600
Study: 23153657

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (BEV)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Grid laser photocoagulation (GLP)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Switching therapy for non-responders
Number of subjects: 44
Study: 20805433

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 241
Study: 18556343

Group type: EXPERIMENTAL
Intervention: Insulin injections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral antidiabetes drugs (OADs)
Number of subjects: 0
Study: 15739544

Group type: EXPERIMENTAL
Intervention: Enoxaparin treatment (40 mg subcutaneously once daily)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 170
Study: 12952844

Group type: EXPERIMENTAL
Intervention: Moderate to severe OSA patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Moderate to severe OSA female patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control female subjects
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mild OSA patients
Number of subjects: 20
Study: 10912887

Group type: EXPERIMENTAL
Intervention: Specific inspiratory muscle training (SIMT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham training (Control)
Number of subjects: 20
Study: 8866698

Group type: EXPERIMENTAL
Intervention: AMPT
Number of subjects: 17

Group type: COMPARATOR
Intervention: Diphenhydramine (active control)
Number of subjects: 17
Study: 1422931

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine at 20 degrees C
Number of subjects: 102

Group type: COMPARATOR
Intervention: 0.5% bupivacaine at 5 degrees C
Number of subjects: 102
Study: 6438014

Group type: EXPERIMENTAL
Intervention: Enteral nutritional support (constant infusion of a defined diet by needle catheter jejunostomy, started at 12 hours postoperatively, reaching 3000 kcal/day within 72 hours)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional nutritional treatment (control group)
Number of subjects: 18
Study: 31106550

Group type: EXPERIMENTAL
Intervention: Methadone (0.2 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fentanyl (0.003 mg/kg)
Number of subjects: 0
Study: 28296480

Group type: EXPERIMENTAL
Intervention: High-dose group (HDG) - 3 classes per week for 12 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-dose group (LDG) - 2 classes per week for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: High-dose group (HDG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-dose group (LDG)
Number of subjects: 30
Study: 25272965

Group type: EXPERIMENTAL
Intervention: computer-assisted cognitive-behavioral therapy and/or medication management (ITV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: usual care (UC)
Number of subjects: 0
Study: 24136890

Group type: EXPERIMENTAL
Intervention: Prognostic model for overall survival (OS) in men treated with second-line chemotherapy
Number of subjects: 1243
Study: 21962588

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Computed tomography angiography (CTA)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Both CEUS and CTA
Number of subjects: 395
Study: 19220503

Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 0